Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog

The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.

Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog

A safety warning regarding the potential risk of suicidal ideation and behaviors associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.

The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, diminishing the efficacy of oral contraceptives could not be dismissed.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

According to the TGA's safety alert, updated product warnings have been issued for this class of prominent medications. These drugs are formally utilized in Australia for managing type 2 diabetes and obesity, and the update follows investigations conducted by international regulatory bodies.

Source Information

Originally published by WAtoday.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Drug Safety

All Drug Safety articles →

Health & Wellness

Peptides: Lab Finds Issues in 30% of Vials as FDA Panel Considers Looser Rules

Peptides are rapidly gaining traction for various health and wellness claims, but a recent lab analysis revealed significant quality control issues in a substantial percentage of tested vials. As the FDA panel prepares to discuss potentially easing restrictions, understanding the risks and the science behind these compounds is crucial.

7 min read

Medication Safety

Compounded Ozempic and Zepbound Still Widely Available After Shortages End

Despite the FDA declaring an end to drug shortages for popular weight loss medications, a new study finds compounded versions remain easily accessible. Understanding the safety implications and regulatory landscape is crucial for patient health.

8 min read

Medication Safety

Study Links GLP-1 Medications To Rare Vision Issue

New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.

6 min read

More in Health

Health

Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk

Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.

4 min read

Health

Obesity Crisis in America Meets Ozempic Boom: Data Shows GLP-1 Hotspots

A recent report highlights the increasing use of GLP-1 medications like Ozempic and Mounjaro across the United States, with some states showing greater adoption than others. The data suggests a correlation between obesity rates and GLP-1 prescription rates, particularly in the South and Midwest.

3 min read

Health

Why Indians Should Use Ozempic Cautiously: Understanding the Reason

With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.

3 min read